Trentham D E, Dynesius-Trentham R A, Orav E J, Combitchi D, Lorenzo C, Sewell K L, Hafler D A, Weiner H L
Department of Medicine, Beth Israel Hospital, Boston, MA.
Science. 1993 Sep 24;261(5129):1727-30. doi: 10.1126/science.8378772.
Rheumatoid arthritis is an inflammatory synovial disease thought to involve T cells reacting to an antigen within the joint. Type II collagen is the major protein in articular cartilage and is a potential autoantigen in this disease. Oral tolerization to autoantigens suppresses animal models of T cell-mediated autoimmune disease, including two models of rheumatoid arthritis. In this randomized, double-blind trial involving 60 patients with severe, active rheumatoid arthritis, a decrease in the number of swollen joints and tender joints occurred in subjects fed chicken type II collagen for 3 months but not in those that received a placebo. Four patients in the collagen group had complete remission of the disease. No side effects were evident. These data demonstrate clinical efficacy of an oral tolerization approach for rheumatoid arthritis.
类风湿性关节炎是一种炎症性滑膜疾病，被认为涉及T细胞对关节内抗原的反应。II型胶原蛋白是关节软骨中的主要蛋白质，也是这种疾病的潜在自身抗原。对自身抗原的口服耐受可抑制T细胞介导的自身免疫性疾病的动物模型，包括两种类风湿性关节炎模型。在这项涉及60例重度活动性类风湿性关节炎患者的随机双盲试验中，服用鸡II型胶原蛋白3个月的受试者肿胀关节和压痛关节数量减少，而接受安慰剂的受试者则未减少。胶原蛋白组有4例患者疾病完全缓解。未发现明显副作用。这些数据证明了口服耐受方法对类风湿性关节炎的临床疗效。
